Tarsus Pharmaceuticals, Inc. (TARS)
About Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $451.4M
- Net income
- -$66.4M
- Total assets
- $562.2M
- Market cap
- $2.6B
- Operating margin
- -15.7%
- Net margin
- -14.7%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $451.4M
- Operating expenses
- $522.3M
- Operating income
- -$71.0M
- Income tax
- $2.1M
- Net income
- -$66.4M
- EPS (basic)
- $-1.59
- EPS (diluted)
- $-1.59
Balance sheet
- Total assets
- $562.2M
- Current assets
- $522.8M
- Total liabilities
- $218.7M
- Current liabilities
- $135.7M
- Shareholders’ equity
- $343.4M
Cash flow
- Operating cash flow
- -$12.5M
- Investing cash flow
- -$42.1M
- Financing cash flow
- $143.4M
- Net cash flow
- $88.8M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $2.6B
- EPS (diluted)
- $-1.59
- Shares outstanding
- 43.5M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Oct 16, 2020
Tarsus Pharmaceuticals, Inc. (TARS) Stock Price
- Reported a net loss of $66.4M in FY2025.
- Revenue grew 691% from FY2021 to FY2025.
- Trading 29% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Tarsus Pharmaceuticals, Inc..
Write a review
News about Tarsus Pharmaceuticals, Inc.
News & sentiment via Polygon.io
Tarsus Pharmaceuticals, Inc.: frequently asked questions
Is Tarsus Pharmaceuticals, Inc. an American company?
Tarsus Pharmaceuticals, Inc. is a US-based company headquartered in Irvine, California, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Tarsus Pharmaceuticals, Inc. headquartered?
Tarsus Pharmaceuticals, Inc. is headquartered in Irvine, California, United States.
Is Tarsus Pharmaceuticals, Inc. publicly traded?
Yes — Tarsus Pharmaceuticals, Inc. is a publicly traded company. Its stock trades under the ticker symbol TARS on the NASDAQ.
What does Tarsus Pharmaceuticals, Inc. do?
Tarsus Pharmaceuticals, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
